Your Weight and Your Liver: A Chattanooga Physician on GLP-1s and Fatty Liver Disease

I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. I read every patient chart myself, and I read the labs that come with it. Weight is what people watch, but the liver is often where the quiet damage of a metabolic problem shows up first. The good news is that the same thing driving the weight is usually driving the liver — which means treating one tends to help the other.

Fatty Liver Disease Is a Metabolic Problem, Not a Drinking Problem

The condition now called metabolic dysfunction-associated steatotic liver disease — fatty liver disease, in plain language — is the buildup of fat inside liver cells in people who do not drink heavily. It travels with the same company as excess weight: insulin resistance, high triglycerides, elevated blood sugar. Left alone, that fat can progress to inflammation and scarring. It is now one of the most common liver conditions in the country, and most people who have it do not know it.

Here is the part that matters for anyone carrying extra weight in Chattanooga: fatty liver is not a separate disease you caught. It is the liver’s version of the metabolic problem you may already be treating. And weight loss is the single most effective lever we have to reverse it — which is exactly why the GLP-1 class, and the drugs coming after it, are being studied so intensively for the liver.

The Frontier: Adding Glucagon to Target the Liver Directly

The current GLP-1 medications work mainly on appetite and blood sugar. The next frontier adds a second hormone — glucagon — and glucagon happens to act powerfully on the liver. The leading example is survodutide, a once-weekly dual agonist that activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 side curbs appetite; the glucagon side raises energy expenditure and pulls fat directly out of the liver.

The Phase 3 data are notable. In the SYNCHRONIZE-1 obesity trial (76 weeks), survodutide produced about 13.0 percent average weight loss at the 6.0 mg dose versus 5.4 percent on placebo (Le Roux CW et al, New England Journal of Medicine 2026, PMID 42253238). But the liver numbers are the real story. In the companion SYNCHRONIZE-MASLD trial, about 84 percent of participants achieved at least a 30 percent reduction in liver fat on MRI, versus about 24 percent on placebo (SYNCHRONIZE-MASLD, Nature Medicine 2026, PMID 42252333). In an earlier Phase 2 study using liver biopsies, about 62 percent of patients on the 4.8 mg dose saw their liver disease improve without worsening of scarring, versus 14 percent on placebo (Sanyal AJ et al, New England Journal of Medicine 2024; 391:311–319). Trial averages, not guarantees — individual results vary.

What the Liver Data Actually Mean for You

The lesson of the survodutide story is bigger than one drug. It is proof that the weight on your body and the fat in your liver respond to the same treatment, often in lockstep — and sometimes the liver improves even before the scale fully catches up. That reframes the whole conversation. Treating your weight is not just about how you look or how your clothes fit. It is one of the most direct things you can do for an organ you will never see.

You do not need to wait for an investigational drug to act on that. Meaningful weight loss with the approved medications we have today already moves liver fat in the right direction, because the mechanism — less excess fat, better insulin sensitivity — is the same. What you need is a physician who is actually looking at your liver markers, not just your weight chart.

What I Do for Patients in Chattanooga Today

At Summit, I treat the metabolic problem, not just the number on the scale. That means I look at the whole picture — weight, blood sugar, triglycerides, liver markers — and I use the approved tools we have to move all of them in the same direction.

This is where a physician-led program and a refill mill genuinely diverge. A questionnaire scored by software prescribes a dose. It does not read your labs, notice a metabolic pattern, or connect your weight to your liver. That connection is the entire point of metabolic medicine — and it is why I read every chart myself before anyone at Summit gets a plan.

And because Summit builds an exit strategy into every plan — get you to your weight, then taper the medication — the metabolic gains, including a healthier liver, are something we work to make durable rather than rented month to month.

The Bottom Line for Chattanooga

Fatty liver disease is one of the clearest signs that excess weight is a whole-body, whole-organ problem — and the newest drug science confirms that treating the weight treats the liver. The frontier agents are exciting, but you do not have to wait for them. If you have been told you have a fatty liver, or you carry the metabolic risk that comes with it, the most powerful move available to you in Tennessee today is structured, physician-led weight loss with someone reading the labs.

You can apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.